This pilot study sponsored by HealthPartners Institute explores a novel non-invasive treatment for early-stage Alzheimer's disease (AD) using rs-fMRI-guided iTBS. Given the limited efficacy of existing FDA-approved AD medications, this approach may represent a significant advancement in AD management, potentially addressing a substantial unmet medical need. The Alzheimer's market is projected to grow significantly, driven by the increasing prevalence of the disease, which currently affects 6.2 million individuals in the U.S. alone. The study's completion and subsequent results could position HealthPartners Institute favorably in the competitive landscape of AD therapies, particularly if efficacy is demonstrated. However, the absence of expanded access may limit immediate commercial opportunities.